The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)

• All 3 of these companies are good established, with coagulated maturation prospects.

• Each faces immoderate struggles, but each are paying shareholders to hold for stronger results.

• Dividend-paying stocks tin truly boost an idiosyncratic investor's portfolio.

• 10 stocks we similar amended than Pfizer ›

If you're successful the marketplace for immoderate no-brainer dividend stocks, I person immoderate bully and less-good quality for you. The bully quality is that investing successful steadfast and increasing dividend-paying stocks is simply a solid, no-brainer determination -- due to the fact that dividend payers tin beryllium almighty investments. Unfortunately, though, hardly immoderate banal qualifies arsenic a no-brainer investment.

For champion results, usage your encephalon to travel and support up with immoderate companies successful which you invest. Here are a fistful of coagulated dividend-paying contenders for your semipermanent portfolio.

First, though, conscionable successful lawsuit you're not fired up astir dividend-paying stocks, cheque retired the array beneath -- arsenic it mightiness astonishment you.

Data source: Ned Davis Research and Hartford Funds.

See? Dividend stocks are not conscionable for your grandparents. Their coagulated show shouldn't beryllium surprising, either, due to the fact that for a company's absorption to consciousness unafraid astir committing to an ongoing dividend payment, the institution typically needs to person grown to a definite size with reasonably reliable income. Here are immoderate promising dividend payers to consider.

According to our Motley Fool Money research, the champion high-yield savings accounts offered involvement rates of astir 4% to 4.3% successful January. Invest successful shares of Pfizer (NYSE: PFE), though, and you're looking astatine a abdominous dividend output of, recently, 6.81%!

The banal has been successful a slump successful caller years successful portion owed to shrunken request for its COVID-19 vaccine and COVID-19 treatment, Paxlovid, arsenic good arsenic the expirations of patent extortion for respective cardinal drugs. But the institution has a batch much going connected than that -- specified arsenic immoderate investments that tin effect successful an approved GLP-1 weight-loss cause for Pfizer.

Pfizer's banal is enticing, too, with a caller forward-looking price-to-earnings (P/E) ratio of 8.5, good beneath its five-year mean of 9.8.

Verizon Communications (NYSE: VZ) sports a dividend precocious yielding adjacent more than Pfizer: 6.93%! Better still, Verizon has been expanding its payout for 19 years successful a enactment (though mostly not with immense increases).